Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.
Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the potential of the epigenome, the company aims to create new therapeutic pathways that modify biological functions without changing the underlying DNA sequence. This approach seeks to provide effective treatments for complex and widespread diseases, positioning Tune Therapeutics at the forefront of advancements in epigenetic medicine.
GraphWear Technologies Inc. is a Philadelphia-based company that develops an advanced nanotechnology sensing platform capable of non-invasively monitoring vital body metrics in real-time through sweat, breath, and saliva. The company specializes in wearable patch sensors that measure lactic acid and glucose levels, offering solutions for dehydration monitoring and glucose detection. These devices are particularly beneficial for professional sports teams, college athletics, and amateur athletes, as they help optimize performance and prevent dehydration. Founded in 2015, GraphWear aims to revolutionize healthcare by providing continuous monitoring of hydration and sugar levels without the need for blood or urine samples, using innovative technology to ensure a hassle-free health tracking experience.
Asher Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy drugs for cancer treatment. Founded in 2019 and headquartered in South San Francisco, California, the company aims to create innovative therapeutic solutions to improve patient outcomes in oncology. Asher Bio leverages advanced technologies and research to enhance the effectiveness of immune-based therapies, positioning itself as a key player in the evolving field of cancer treatment.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.
Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.
Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, specializing in cellular engineering and genome analysis through CRISPR-Cas9 technology. Founded in 2011, the company provides a gene editing platform that allows for targeted modifications in the genome. Its applications span various sectors, including human and animal therapeutics, agricultural biotechnology, and industrial biotechnology. Caribou's solutions facilitate the development of new disease models, enhance traits in plants, and support functional genomic screens. The company aims to advance both basic and applied biological research, leveraging its transformative capabilities to impact therapeutic development and bioproduction.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses.
It was founded in 2017 and is based in Cambridge, Massachusetts.
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses.
It was founded in 2017 and is based in Cambridge, Massachusetts.
Symbiome, Inc. is a skincare company based in San Francisco, California, specializing in products formulated with microbiomic and plant-based ingredients. Founded in 2017, the company aims to provide skincare solutions that reflect natural principles and utilize ancestral ingredients. Originally known as Persona Biome, Inc., it adopted the name Symbiome, Inc. in December 2019. By combining scientific research with traditional knowledge, Symbiome develops products designed to promote healthy skin.
QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.
Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Wild Type, Inc. is a San Francisco-based company that produces meat, poultry, and seafood through cellular agriculture, eliminating the need for raising or slaughtering animals. Founded in 2016, Wild Type offers a sustainable alternative to traditional food sources, addressing critical issues such as climate change, food security, and public health. By leveraging advanced cellular agriculture technologies, the company aims to redefine how society sources healthy and delicious meat, contributing to a more sustainable food ecosystem.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. It specializes in developing and commercializing silk biomaterial technologies aimed at improving vaccine delivery and storage. The company has created the MIMIX microneedle platform, which facilitates transdermal delivery of vaccines and therapies, and the MATRIX formulation and drying platform, which enhances the stability of vaccines, therapeutics, and diagnostic products. By utilizing a silk-derived protein, Vaxess enables vaccines to be stored and transported without refrigeration, thereby reducing distribution costs and increasing access to essential healthcare products globally.
Comet Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. It specializes in developing novel small-molecule treatments targeting various diseases, particularly orphan neurological disorders. The company's core innovation is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism. This therapeutic approach enables healthcare providers to address significant unmet medical needs in the treatment of these complex conditions.
Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.
Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.
Alessa Therapeutics, Inc. is a pre-clinical stage company based in San Francisco, California, focused on developing localized treatments for solid organ diseases, particularly prostate cancer. Founded in 2018, the company specializes in a drug delivery implantable system that administers anti-androgen drugs directly to prostate tumors. This innovative system allows for sustained and localized treatment, minimizing systemic exposure and enhancing the efficacy of therapy for patients. By concentrating on specific organ diseases, Alessa Therapeutics aims to improve treatment outcomes and quality of life for patients suffering from these conditions.
Tangible Science, LLC specializes in the development of innovative products aimed at enhancing the comfort of contact lens users, particularly those suffering from dry eye conditions. Founded in 2011 and based in Redwood City, California, the company has created a polymer coating technology that provides a bio-compatible and highly hydrated surface for contact lenses. This technology helps maintain the natural tear film, significantly reducing discomfort associated with lens wear. Tangible Science's product offerings include contact lens coatings, cleaners, rejuvenators, and a line of disposable lenses, all designed to improve the overall experience for patients, eye care professionals, and contact lens manufacturers.
Operator of a biotechnology company intended to develop medicine to reverse cancer cell immortality. The company's medicine specializes in inhibiting cancer cell immortality by undergoing immortalization process, leaving healthy cells intact, enabling patients to get cured of diseases such as cancer.
Nobell Foods is a biotech company based in San Francisco, California, that specializes in developing and producing animal-based food substitutes using plant materials. Founded in 2016, the company aims to transform plants into bioreactors to generate protein, unlocking their potential to create innovative food alternatives. By focusing on plant-based solutions, Nobell Foods seeks to provide sustainable options that can replace traditional animal products, contributing to a more environmentally friendly food system.
Photoswitch Biosciences, Inc. is a biotechnology company based in Menlo Park, California, founded in 2008. The company specializes in developing innovative tools for drug screening and safety pharmacology studies, focusing on excitable membrane biology. It manufactures instruments that control the function of ion channels and offers optical kinetic plate readers and voltage-sensitive dyeing devices. These products enable the assay of electrical properties in induced pluripotent stem cell cardiomyocytes, whether in a spontaneously active or optically paced state. By utilizing channelrhodopsin-based optical control, Photoswitch Biosciences simplifies the screening and testing of new drug candidates, providing valuable resources for biotechnology researchers.
Invenio Imaging, Inc. is a privately held company founded in 2012 and based in Santa Clara, California. The company specializes in developing advanced technology for non-destructive microscopic analysis of the molecular composition of tissues and materials. Its primary product is a multi-modal coherent Raman scattering microscope, which is designed for both research and high-value medical applications. This innovative imaging system facilitates intraoperative histology by providing high-resolution images that allow researchers to examine tissue specimens from multiple surgical sites. Invenio Imaging's technology is underpinned by research from Prof. Sunney Xie at Harvard University and has received funding from the National Science Foundation and the National Institutes of Health's Small Business Innovation Research programs.
Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. The company integrates automation, machine learning, and genomics to enhance its platform, which aids in optimizing microbial strains and improving the efficiency of production processes. By leveraging big data and artificial intelligence, Zymergen collaborates with clients to engineer novel molecules from microbes, thereby advancing product development. Founded in 2013 and headquartered in Emeryville, California, Zymergen also has offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, enabling it to serve a global clientele effectively.
QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.
Principia Biopharma Inc. is a late-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead candidate, rilzabrutinib, is an inhibitor currently undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 and Phase 2 trials for immune thrombocytopenia and IgG4-related disease, respectively. Additionally, Principia is advancing PRN2246/SAR442168, aimed at treating multiple sclerosis and other central nervous system disorders, which is in Phase II trials. Another candidate, PRN473, is in Phase I trials for various immune-mediated diseases. Principia Biopharma collaborates with Genzyme Corporation to explore treatments for relapsing and progressive multiple sclerosis, enhancing its commitment to addressing significant unmet medical needs in immunology and oncology. Established in 2008, the company operates as a subsidiary of Sanofi.
Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. The company's lead product, AL001, is a humanized recombinant monoclonal antibody currently in phase II clinical trials for frontotemporal dementia. Additionally, AL101 is in phase I clinical trials for various neurodegenerative diseases, while AL002 and AL003 are undergoing phase 1b trials specifically for Alzheimer's disease. Alector is leveraging advancements in antibody technology, neuroimmunology, and human genetics to create innovative therapeutics. The company maintains a collaboration with Adimab, LLC, which aids in the discovery and optimization of antibody therapeutics. Alector has a pipeline of ten programs in the research and development stage and aims to advance several candidates through pre-clinical development within the next two years. Founded in 2013, Alector is headquartered in South San Francisco, California.
Cereius, Inc. is a privately owned, pre-clinical stage company based in Durham, North Carolina, focused on developing innovative small-molecule therapies for treating brain metastasis specifically in patients with HER2-positive breast cancer. Established in 2017, the company employs novel radiolabeling chemistries that improve the uptake and retention of radionuclides in targeted tumors while reducing uptake in normal tissues. This approach aims to significantly enhance both the therapeutic index and diagnostic contrast of targeting agents, positioning Cereius as a key player in the advancement of treatment options for solid tumor brain metastasis.
GraphWear Technologies Inc. is a Philadelphia-based company that develops an advanced nanotechnology sensing platform capable of non-invasively monitoring vital body metrics in real-time through sweat, breath, and saliva. The company specializes in wearable patch sensors that measure lactic acid and glucose levels, offering solutions for dehydration monitoring and glucose detection. These devices are particularly beneficial for professional sports teams, college athletics, and amateur athletes, as they help optimize performance and prevent dehydration. Founded in 2015, GraphWear aims to revolutionize healthcare by providing continuous monitoring of hydration and sugar levels without the need for blood or urine samples, using innovative technology to ensure a hassle-free health tracking experience.
ViewPoint Therapeutics, a biotechnology company founded in 2014 and based in San Francisco, focuses on developing treatments for diseases caused by protein misfolding, particularly cataracts. The company is advancing its research on crystallin stabilizers, which are small molecules designed to prevent and treat age-related cataracts and presbyopia. These stabilizers have shown promise in preclinical models through a systematic screening and optimization process. By targeting protein misfolding, ViewPoint Therapeutics aims to provide effective therapies for common age-related disorders, including cataracts and neurodegenerative diseases, ultimately enhancing treatment options for physicians and their patients.
Magnap is engaged in the development and manufacture of surgical equipment aimed at treating obstructive sleep apnea (OSA). The company's innovative device is a custom, removable external neck accessory that incorporates a magnet. This accessory is worn during sleep and functions by attracting an internal hyoid magnet with sufficient force to prevent airway collapse, thereby keeping the airway open. Magnap's approach offers a minimally invasive surgical treatment option for specific types of sleep apnea, providing healthcare professionals with advanced tools to enhance patient care. The company's clinical trial initiatives are based in the United States.
Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability
Avexegen Therapeutics Inc. is a development stage company focusing on development of drugs and therapies to heal damaged and inflamed gut tissue in patients with Crohn’s Disease and ulcerative colitis. The company was founded in 2014 and is based in San Diego, California.
True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.
Bolt Threads Inc. is a materials company based in Emeryville, California, founded in 2009. The company specializes in the manufacture of innovative fibers and fabrics, including its signature biofabricated silk fibers known as Microsilk. Utilizing proprietary technology and advanced bioengineering concepts, Bolt Threads develops next-generation performance fibers and fabrics aimed at enhancing quality, performance, and design in various sectors, including apparel, footwear, and beauty. The company focuses on sustainable practices by transforming textile waste into new products, positioning itself as a leader in environmentally responsible textile production.
Epiodyne, Inc. is a biopharmaceutical company based in San Francisco, California, focused on developing innovative drugs that target the delta opioid receptors and the brain's opioid peptide system. Established in 2016, Epiodyne aims to create novel analgesics to address neurobehavioral symptoms associated with brain disorders, particularly for patients suffering from opioid use disorder. The company's research is centered on restoring the brain's reward system to effectively treat issues related to compulsivity, self-injury, and addiction, thereby providing new therapeutic options for individuals in need of effective treatment solutions.
Mitokinin, Inc. is a biotechnology company operating in the healthcare sector, established in 2017 and located in New York, New York. The company is engaged in medicinal chemistry efforts aimed at generating kinetin analogs that are specifically optimized to activate PINK1, a protein associated with cellular health. Mitokinin's primary focus is the development of these analogs or their optimized variants as potential treatments for Parkinson's disease, a neurodegenerative condition. The company strives to advance its research in order to contribute to effective therapeutic options for this challenging illness.
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumors. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, which demonstrates a unique mechanism of action and targets derived from antibodies identified through Atreca's innovative discovery platform. ATRC-101 has shown in vitro reactivity with a significant majority of cancer samples, including those from ovarian, non-small cell lung, colorectal, and breast cancer patients. Additionally, the company has established a strategic research collaboration with Merck Sharp & Dohme Corp. to identify antigenic targets of select antibodies with potential applications in oncology. Founded in 2010, Atreca aims to advance its therapies to improve treatment options for cancer patients.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
Vivace Therapeutics, Inc. is a small molecule discovery and development company focused on creating innovative cancer therapeutics by targeting the Hippo pathway, which plays a critical role in tissue regeneration and organ development. Founded in 2014, the company is based in San Mateo, California, and operates with a commitment to advancing novel therapies that can improve outcomes for cancer patients. Vivace Therapeutics emphasizes a capital-efficient and modality-indifferent approach, collaborating with leading academic laboratories to leverage cutting-edge research. Its experienced management team and top-tier scientists aim to develop treatments that can be used independently or in combination with existing therapies, ultimately striving to enhance the lives of individuals affected by cancer.
Redwood Bioscience specializes in precision protein-chemical engineering to create optimized biotherapeutics. The company employs site-specific modification technology, which addresses the challenges of conjugating biologics with synthetic molecules, resulting in homogeneous hybrid biotherapeutics. These hybrid drugs combine the specificity and extended half-life of biologics with the potency of synthetic peptides and small molecules. By utilizing modified carrier scaffolds, Redwood develops peptide therapeutics aimed at enhancing serum half-lives and antibody-drug conjugates that exhibit improved potency and reduced toxicity. Additionally, the company is expanding the chemical space of protein drugs by creating heterofunctional products with unique architectures. Redwood collaborates with partners to enhance the value of existing programs and to jointly develop innovative compounds while also pursuing its own internal biotherapeutic programs.
Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in the development and commercialization of innovative research tools that facilitate protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. This system employs microfluidics technology to isolate single cells in micro-wells, lysing them and performing SDS-PAGE separation on each lysate. Researchers utilize Zephyrus's tools to explore critical areas such as cancer biology, stem cell research, neurology, and broader human disease studies, ultimately contributing to advancements in diagnostics and therapeutics. As of March 2016, Zephyrus operates as a subsidiary of Bio-Techne Corp.
Symic Biomedical, based in San Francisco, California, is a biotechnology company focused on developing matrix regulator therapeutics to address various health conditions. Founded in 2012, the company aims to treat osteoarthritis and cardiovascular diseases by targeting and inhibiting matrix degradation and pathological inflammatory responses associated with injury and disease. Its therapeutics are designed to bind to specific targets within the extracellular matrix, presenting potential applications in fibrosis, oncology, and central nervous system disorders. As a subsidiary of Symic Holdings, LLC, Symic Biomedical is dedicated to advancing therapeutic solutions that can improve patient outcomes in these critical areas of healthcare.
Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, focused on developing cell-permeable macrocyclic peptide therapeutics. Founded in 2012 by Professors Matt Jacobson and Scott Lokey, the company utilizes proprietary computational design algorithms and innovative synthetic chemistry to create macrocycles targeting significant clinical challenges. Their approach involves an iterative design process that leverages large virtual libraries of diverse macrocycle scaffolds, selected for their permeability. Circle Pharma aims to address unmet clinical needs, particularly in the treatment of cancer, by focusing on intracellular protein-protein interactions through its novel macrocycle therapies, which can be delivered via multiple routes, including oral administration. The company's work is intended to enable healthcare professionals to advance internal development efforts in this critical area of medicine.
Sentieon, Inc. is a biotechnology company founded in 2014 and headquartered in Mountain View, California, specializing in cloud-based bioinformatics solutions for the life sciences and clinical markets. The company develops a suite of bioinformatics tools designed for the efficient processing of genomics data, focusing on high accuracy and computational efficiency. Key products include Sentieon DNAseq, which facilitates germline DNA analysis, and Sentieon TNseq, used for detecting somatic variants in tumor-normal samples. Sentieon's software solutions are characterized by their scalability, deployability, and upgradability, allowing them to adapt to various user needs. The company's advanced algorithms and robust software implementation ensure rapid turnaround times and consistent results, benefiting scientists, clinicians, and patients by enhancing precision in genomic data analysis.
SiteOne, Inc. is a biotechnology company focused on developing innovative therapeutics and diagnostics for the treatment of acute and chronic pain. Established in 2010 and based in Bozeman, Montana, the company aims to provide safe and effective alternatives to existing pain management therapies, including nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. SiteOne's lead therapeutic candidates are selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is essential for transmitting pain signals in the nervous system. By targeting this specific channel, SiteOne seeks to offer new solutions for patients suffering from various pain conditions.
Pionyr Immunotherapeutics Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative cancer immunotherapies. Established in 2015, the company aims to enhance the body’s antitumor immunity by targeting the tumor microenvironment. Pionyr employs advanced technologies for novel target discovery and antibody generation, which underpin its next-generation immuno-oncology therapeutics. Central to its strategy is the Myeloid Tuning™ approach, designed to specifically modify the cellular composition within the tumor microenvironment, thereby improving the immune system's ability to combat tumors.
iPierian is engaged in the research and development of therapies aimed at treating neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease. The company utilizes induced pluripotent stem cells to facilitate drug discovery and development, focusing on addressing significant unmet medical needs. In particular, iPierian is developing therapies and monoclonal antibodies that target Tauopathies, which are diseases characterized by the accumulation of tau protein in the brain. These therapies aim to slow the spread of tau throughout the brain, thereby inhibiting the progression of associated diseases.